Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Cash & Equivalents data on record, last reported at $55.0 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 63.33% year-over-year to $55.0 million; the TTM value through Sep 2025 reached $55.0 million, up 63.33%, while the annual FY2024 figure was $21.9 million, 83.27% down from the prior year.
  • Cash & Equivalents reached $55.0 million in Q3 2025 per DNTH's latest filing, up from $12.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $329.7 million in Q1 2024 and bottomed at $9.3 million in Q1 2025.
  • Average Cash & Equivalents over 4 years is $87.1 million, with a median of $40.3 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 1320.49% in 2024, then crashed 97.19% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $15.4 million in 2022, then skyrocketed by 753.84% to $131.2 million in 2023, then crashed by 83.27% to $21.9 million in 2024, then skyrocketed by 150.59% to $55.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $55.0 million in Q3 2025, $12.0 million in Q2 2025, and $9.3 million in Q1 2025.